
Takeda's US subsidiary, Takeda America Holdings, has agreed to acquire the vaccine specialist company LigoCyte Pharmaceuticals for an upfront payment of $60 million in a move intended to bolster and expand the company's vaccine business.

Takeda's US subsidiary, Takeda America Holdings, has agreed to acquire the vaccine specialist company LigoCyte Pharmaceuticals for an upfront payment of $60 million in a move intended to bolster and expand the company's vaccine business.

Merck Returns Brinavess Rights to Cardiome; Sigma-Aldrich Expands in Scotland; and More.

Merck Serono's Asceneuron is the third company to be spun off from the company's Entrepreneur Partnership Program that was launched to mitigate the impact from recent restructuring at its Geneva site.

Several Big Pharma companies strengthen their manufacturing presence in Russia.

New European Pharmacopoeia chapter aims to resolve problems with applying the harmonized UDU test to large sample sizes.

Will the next US President support the backbone of our industry?

Foreign firms struggle against stricter patent laws, but all is not lost.

Today's pharmaceutical companies are striving to reduce costs and maximize efficiencies, and must make decisions on the best way to deploy their limited resources.

Only the strong survive when it comes to pharmaceutical packaging and shipping.

Working together affords many unseen opportunities for pharmaceutical innovation.

Recent news stories have reported that FDA scientists have been suspected of leaking confidential, commercial, and trade secret information to the media.

FDA launches BeSafeRx program and releases guidance for industry.

Q&A with David Elder and Richard Wright of Strategic Compliance Consulting, PAREXEL International. Both Elder and Wright formerly served with FDA.

A new report has forecast that the global biopharmaceutical market will be worth more than $320 billion by 2020, up from just $138 billion in 2011.

The European Medicines Agency has updated its guidance on biosimilar medicines, with the aim of helping companies to avoid unnecessary repetition of clinical trials.

The President's Council of Advisors on Science and Technology (PCAST) released a report containing recommendations for boosting innovation in drug discovery and development.

Sanofi is planning to shed approximately 900 jobs in France in the lead up to 2015 as it seeks to implement certain key strategic objectives.

Mallinckrodt Agrees to Acquire CNS Therapeutics; Sanofi Outlines R&D Restructuring; and More.

Although CPhI, ICSE, InnoPak and and P-Mec won’t begin until 9 October, you can start your CPhI experience a dary earlier on 8 October by attending the preshow Pre-Connect Conference.

The European Medicines Agency has abolished its Cell-based Product Working Party and Gene Therapy Working Party, with the aim of improving efficiencies and optimizing the use of available expertise.

Watson Laboratories has recalled two lots of hydrocodone bitartrate and acetaminophen tablets.

Novo Nordisk has invested $100 million in expanding its research centre in Beijing, China, to 12000 m2.

ISPE has published a new guidance titled ISPE Good Practice Guide: Quality Laboratory Facilities, which defines design guidelines for quality laboratories.

Pfizer Launches Joint Venture In China; Spectrum Sartorius Opens New Facility In Germany; And More.

Johnson & Johnson has announced plans to open four innovation centers in California, Boston, London, and China, with the aim of accelerating early innovation and facilitating collaboration and investment opportunities.

Our company needs more stability storage. What issues should we consider when deciding whether to build our own biorepository facility or outsource our storage?

Teva announced an agreement in which Bayer HealthCare will acquire the US-based animal health business of Teva Pharmaceutical Industries for up to $145 million. The transaction is expected to close in 2013, subject to antitrust clearance and other conditions.

The European Generic Medicines Association (EGA) has raised concerns about the potential fees to be charged by the European Medicines Agency for pharmacovigilance activities

Delaying the onset of Alzheimer's disease by just five years could reduce the cost for care of Alzheimer's patients by $447 billion a year by 2050, according to a new PhRMA report.

Cambridge Major Laboratories Expands API Manufacturing Facility; Spectrum Completes Acquisition of Allos Therapeutics; and More.